國家衛生研究院 NHRI:Item 3990099045/8699
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 856691      線上人數 : 827
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/8699


    題名: Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells
    其他題名: Targeting of surface α-enolase inhibits the invasiveness of pancreatic cancer cells
    作者: Principe, M;Ceruti, P;Shih, NY;Chattaragada, MS;Rolla, S;Conti, L;Bestagno, M;Zentilin, L;Yang, SH;Migliorini, P;Cappello, P;Burrone, O;Novelli, F
    貢獻者: National Institute of Cancer Research
    摘要: Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy characterized by rapid progression, invasiveness and resistance to treatment. We have previously demonstrated that most PDAC patients have circulating antibodies against the glycolytic enzyme alpha-enolase (ENO1), which correlates with a better response to therapy and survival. ENO1 is a metabolic enzyme, also expressed on the cell surface where it acts as a plasminogen receptor. ENO1 play a crucial role in cell invasion and metastasis by promoting plasminogen activation into plasmin, a serine-protease involved in extracellular matrix degradation. The aim of this study was to investigate the role of ENO1 in PDAC cell invasion. We observed that ENO1 was expressed on the cell surface of most PDAC cell lines. Mouse anti-human ENO1 monoclonal antibodies inhibited plasminogen-dependent invasion of human PDAC cells, and their metastatic spreading in immunosuppressed mice was inhibited. Notably, a single administration of Adeno-Associated Virus (AAV)-expressing cDNA coding for 72/1 anti-ENO1 mAb reduced the number of lung metastases in immunosuppressed mice injected with PDAC cells. Overall, these data indicate that ENO1 is involved in PDAC cell invasion, and that administration of an anti-ENO1 mAb can be exploited as a novel therapeutic option to increase the survival of metastatic PDAC patients.
    日期: 2015-05
    關聯: Oncotarget. 2015 May;6(13):11098-11113.
    Link to: http://dx.doi.org/10.18632/oncotarget.3572
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000359006400034
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84929611036
    顯示於類別:[施能耀] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB25860938.pdf2845KbAdobe PDF495檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋